Trials / Completed
CompletedNCT02316821
The Phase II Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes; TSUBAKI Study
RTA 402 Phase 2 Clinical Trial (A Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients With Chronic Kidney Disease and Type 2 Diabetes)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 216 (actual)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and efficacy of RTA 402 in chronic kidney disease (CKD) patients with type 2 diabetes in a double-blind, placebo-controlled study when this compound is administered once daily for 16 weeks in an intrapatient dose escalation design.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RTA 402 | |
| DRUG | Placebo |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2016-05-01
- Completion
- 2017-09-01
- First posted
- 2014-12-15
- Last updated
- 2017-10-27
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02316821. Inclusion in this directory is not an endorsement.